Skip to main content

Day: January 22, 2024

Power Solutions International (PSI) Showcases Engines at PowerGen Trade Show

Leading Power Generation Solutions Provider to Exhibit at PowerGen in New Orleans WOOD DALE, Ill., Jan. 22, 2024 (GLOBE NEWSWIRE) — Power Solutions International, Inc. (the “Company” or “PSI”) (OTC Pink: PSIX), a leader in the design, engineering and manufacture of emission-certified engines and power systems, is excited to announce its participation in PowerGen International, taking place from January 23 to January 25 at the Ernest N. Morial Convention Center in New Orleans. The event brings together industry professionals, experts and innovators to explore the latest advancements in power generation technologies. PSI is proud to be a part of the event, showcasing its 20-liter and 2.4-liter Turbo engines in Booth 2544. The engines are part of PSI’s Power Systems line, known in the industry for their exceptional performance, reliability...

Continue reading

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. “I am excited to welcome Kaya to Neumora. As we progress toward the potential commercialization of navacaprant and further advance our pipeline, her extensive commercial expertise in neuropsychiatry will...

Continue reading

Dorman rolls into 2024 with more than 300 new products, including more aftermarket exclusives and Dorman® OE FIX™ innovations

COLMAR, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) — Dorman Products, Inc. (NASDAQ:DORM) hasn’t lost any momentum from a successful 2023 that featured more than 3,000 new product launches, and is announcing 325 new motor vehicle parts to start the new year. These January 2024 releases represent millions of new sales opportunities for automotive parts distributors, retailers, and repair shops and reinforce Dorman’s position as a leading aftermarket provider of comprehensive powertrain repair solutions. This month’s new releases include an innovative Dorman® OE FIX™ transmission oil cooler bypass valve, with coverage for approximately 1.5 million select Chevrolet, GMC and Cadillac SUVs and pickup trucks. On certain models, when the transmission overheats, doesn’t generate sufficient heat, or leaks fluid, it can be due to corrosion,...

Continue reading

Mercury Introduces Direct RF System-On-Module Powered by Intel Agilex FPGA

Mercury’s DRF2580 System-On-ModuleMercury’s DRF2580 System-On-ModuleANDOVER, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing power to the edge, today introduced a Direct RF system-on-module (SOM) that uses Intel Agilex FPGAs to detect and process adversary emissions from a wide portion of the electromagnetic spectrum. Direct RF components and modules directly digitize radio frequency signals at the antenna signal frequency, eliminating the analog signal down conversion stages required by legacy hardware. This approach requires extremely fast converters, high bandwidth digital data links, and powerful real-time digital signal processing. The results are reductions size, weight, power, cost, and latency...

Continue reading

Western Metallica Makes Copper Discovery on Caña Brava Porphyry Project in Peru

Figure 1Caña Brava Project: drone-borne RTP magnetic anomaly map showing the alteration footprints over Caña Brava 1 and Luz Maria.Figure 2Luz Maria Prospect: map showing the outcroppingintrusions, with the average Cu and Mo grades, coincident magnetic anomalies, and other possible intrusion centres below the sedimentary and colluvium cover.TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Western Metallica Resources Corp. (TSXV: WMS) (“Western Metallica” or the “Company”) is pleased to report on a recent discovery at Luz Maria, one of two prospects within the Company’s Caña Brava Project, where recent geochemical and drone-borne magnetometry surveys have confirmed a ~2.7 km by ~1.5 km potassic and phyllic alteration, typical of Andean Cu-Mo porphyry systems, associated to magnetic anomalies and consistent copper grades...

Continue reading

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program. “We are sharpening our clinical focus on the rapidly...

Continue reading

Beneficient Closes Initial Series of Liquidity Transaction Financings of Limited Partner Interests Sourced Through Preferred Liquidity Provider Program (“PLP Program”)

– Closing of $2 Million Liquidity Financing Caps Nearly $10 Million Sourced from PLP Program – – Entered into additional PLP Program Agreements, Increasing the Total Amount of Committed Capital to Funds Party to the PLP Program to $1.5 Billion – – PLP Program now Offered alongside Beneficient’s New Primary Commitment Program for General Partners – DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) — Beneficient (Nasdaq: BENF), a technology-enabled platform providing liquidity and related trust and custody services to holders of alternative assets through its proprietary AltAccess® online platform, today announced key milestones and liquidity transaction financing closings sourced through its expanding Preferred Liquidity Provider Program (“PLP Program”) for general partners. As a result of recent increased participation in the PLP Program,...

Continue reading

Solaris Commences 2024 Drilling Program at Warintza Project

VANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a corporate update including the commencement of the 2024 drilling program at its Warintza Project (“Warintza” or “the Project”) in southeastern Ecuador. Warintza 2024 Drilling Program Underway The 2024 drilling program has commenced with the first rig turning at Warintza East and a total of six rigs planned to be in operation by the end of February. An updated mineral resource estimate is expected in late Q2/24 to take in nearly double the meterage of the prior estimate and deliver major growth at Warintza Central, East and the recent discovery of Warintza Southeast within a common pit shell. Drilling will continue through the updated mineral resource estimate with a...

Continue reading

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including Multiple System Atrophy (MSA), Parkinson’s disease and Lewy Body Dementia. “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “While our primary focus is on the further clinical development...

Continue reading

POET Technologies Upsizes Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Corporation“) (TSXV:PTK, NASDAQ:POET) today announces that, in response to additional interest in its non-brokered private placement previously-announced and described in the Corporation’s news releases of December 11, 2023 and January 16, 2024 (as amended, the “Offering“), the Offering will be upsized. The Offering will now consist of up to 5,100,000 units of the Corporation (the “Units“) at a price of C$1.22 (US$0.90) per Unit for aggregate gross proceeds of up to approximately C$6,222,000 million (US$4,590,000 million). The terms of the Offering are otherwise unchanged from those previously announced. Each Unit...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.